My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

59 60 Next >

AstraZenceca's Tagrisso Shows Survival Benefit In Early-Stage Lung Cancer Settings ↗

March 09, 2023

Via Benzinga

AstraZeneca's Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients ↗

March 09, 2023

Via Benzinga

Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race ↗

March 08, 2023

These companies aren't working on a vaccine, but a monoclonal antibody.

Via Investor's Business Daily

3 No-Brainer Stocks to Buy With $400 Right Now ↗

March 08, 2023

A reasonably small amount of money can go a long way when it's invested in innovative businesses.

Via The Motley Fool

AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting ↗

March 06, 2023

Via Benzinga

AstraZeneca's Debt Overview ↗

March 02, 2023

Shares of AstraZeneca Inc. (NASDAQ:AZN) fell by 5.41% in the past three months. Before having a look at the importance of debt, let's look at how much debt AstraZeneca has.

Via Benzinga

AstraZeneca Plc (AZN) Q4 2022 Earnings Call Transcript ↗

February 09, 2023

AZN earnings call for the period ending December 31, 2022.

Via The Motley Fool

2 Top Biotech Stocks to Buy Right Now ↗

February 09, 2023

These two companies each pay market-beating dividends to shareholders.

Via The Motley Fool

AstraZeneca Stock Jumps As Upbeat Guidance Offsets Mixed Quarterly Report ↗

February 09, 2023

The company's guidance palliated concerns of high expenses this year, an analyst said.

Via Investor's Business Daily

4 AI Stocks That Are Revolutionizing Healthcare ↗

March 06, 2023

With the growing use of AI in healthcare, it has led to a number of stocks that are focused on this industry.

Via InvestorPlace

Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program ↗

March 02, 2023

Via Benzinga

Why Emergent BioSolutions Stock Tumbled by Almost 12% Today ↗

February 28, 2023

It's not a good day for investors when their company reports a shocking plunge into the red.

Via The Motley Fool

Why Compugen Shares Are Up Today ↗

February 28, 2023

The company released its fourth-quarter and full-year results after the bell Monday.

Via The Motley Fool

Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca ↗

February 25, 2023

Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between...

Via Talk Markets

AstraZeneca Earnings Preview ↗

February 08, 2023

Via Benzinga

Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out ↗

February 16, 2023

Seattle Genetics' guidance deliberately excludes a looming opportunity for Padcev.

Via Investor's Business Daily

AstraZeneca Forecasts Growth In 2023 Earnings, Revenue Despite Fall In COVID-19 Products, Plans To Deliver 15 New Medicines This Decade ↗

February 09, 2023

Via Benzinga

AstraZeneca Q4 Earnings Beat, Sales Hurt By COVID Jab ↗

February 09, 2023

Core earnings of $1.38 per share declined 17% year over year on a reported basis and 5% at constant exchange rates (CER).

Via Talk Markets

US Stocks On Recovery Course As Earnings Lend Support: Fed's Hawkish Stance May Unwind Rally In High-Value Names, Says Analyst ↗

February 09, 2023

The see-sawing mood in the market continues as Fed’s data dependency creates volatility. The index futures point to a solidly higher opening on Thursday, signaling a reversal in the sentiment seen in...

Via Benzinga

Beat the Dow Jones With This Unstoppable Dividend Stock ↗

February 08, 2023

This pharmaceutical company has outperformed the Dow Jones index over the last 10 years.

Via The Motley Fool

Danaher Shows Interest In Acquiring Catalent Valued At Significant Premium: Report ↗

February 06, 2023

Danaher Corporation (NYSE: DHR) has reportedly expressed interest in acquiring the contract manufacturer Catalent Inc (NYSE: CTLT).

Via Benzinga

Is Gilead Sciences a Good Stock to Buy Now? ↗

February 06, 2023

Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward.

Via The Motley Fool

Top 5 Health Care Stocks That May Rally ↗

February 03, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Johnson & Johnson's Upcoming Lung Cancer Data Could Offer Another Blockbuster Opportunity, Says Analyst ↗

February 02, 2023

Via Benzinga

3 No-Brainer Dividend Stocks to Buy Hand Over Fist in 2023 ↗

February 01, 2023

These healthcare titans are poised for a strong showing in 2023 and beyond.

Via The Motley Fool

$1,000 Invested In 4 Of The 5 Vaccine Developers Back When WHO Declared COVID-19 An Emergency Yielded Returns ↗

January 30, 2023

The COVID-19 pandemic emerged in 2019 in China and spread to the rest of the globe in early 2020. Since then, the virus has caused more than 6.8 million deaths.

Via Benzinga

Could This Vaccine Become Sanofi's Latest Blockbuster? ↗

January 29, 2023

This vaccine candidate could be approved in newborns and infants later this year.

Via The Motley Fool

Could This Be Novartis' Next Blockbuster Medicine? ↗

January 27, 2023

The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug.

Via The Motley Fool

7 Dividend Stocks to Buy for a Stable Income Stream ↗

January 27, 2023

These are the dividend stocks to buy for a regular income stream and potential capital gains as these stocks trade at attractive valuations.

Via InvestorPlace

Is Johnson & Johnson Still a Good Dividend Stock to Buy? ↗

January 26, 2023

A disappointing fourth-quarter performance has some investors worried about the giant healthcare conglomerate's outlook.

Via The Motley Fool

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.